CAPDM Member News – Apotex Inc., COVID-19 Response

In the face of this global and local pandemic, Apotex Inc. is pleased to advise they have undertaken the following on behalf of all Canadians:

• Shifted priorities to scale up production and re-purposed our plants to manufacture hydroxychloroquine to meet 100% of the current needs of all Canadians with Lupus and Rheumatoid Arthritis (current on-label indications).
• Donated product, including placebo for eight (8) clinical trials in Canada.
• Making available an additional 2 million dosages of hydroxychloroquine to the federal government by donation, to further ensure national availability of hydroxychloroquine during these pandemic times.

This donation and increased production to meet the needs of all Canadians is only made possible by, and underscores the importance of local, domestic manufacturing in Canada.
The thousands of essential workers involved in this effort take great pride in going to work during this pandemic to ensure patients have access to hydroxychloroquine and the hundreds of other products manufactured for the health and well-being of all Canadians.